Insider Selling: Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Insider Sells $179,754.66 in Stock

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) insider Joe Bonaccorso sold 25,461 shares of the company’s stock in a transaction dated Monday, July 22nd. The shares were sold at an average price of $7.06, for a total transaction of $179,754.66. Following the transaction, the insider now owns 106,931 shares in the company, valued at $754,932.86. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Verrica Pharmaceuticals Price Performance

Shares of VRCA stock opened at $7.25 on Friday. The company has a debt-to-equity ratio of 29.58, a quick ratio of 3.04 and a current ratio of 3.17. The company’s 50-day simple moving average is $8.03 and its two-hundred day simple moving average is $6.77. Verrica Pharmaceuticals Inc. has a one year low of $2.86 and a one year high of $11.41.

Verrica Pharmaceuticals (NASDAQ:VRCA) last issued its earnings results on Monday, May 13th. The company reported ($0.44) EPS for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.10. The business had revenue of $3.83 million for the quarter, compared to the consensus estimate of $2.70 million. Verrica Pharmaceuticals had a negative net margin of 905.83% and a negative return on equity of 229.26%. On average, sell-side analysts anticipate that Verrica Pharmaceuticals Inc. will post -1.57 EPS for the current year.

Institutional Investors Weigh In On Verrica Pharmaceuticals

Several hedge funds have recently modified their holdings of VRCA. BML Capital Management LLC lifted its position in shares of Verrica Pharmaceuticals by 20.0% in the 4th quarter. BML Capital Management LLC now owns 180,000 shares of the company’s stock worth $1,318,000 after purchasing an additional 30,000 shares during the period. Avoro Capital Advisors LLC lifted its position in shares of Verrica Pharmaceuticals by 35.4% in the 4th quarter. Avoro Capital Advisors LLC now owns 3,999,999 shares of the company’s stock worth $29,280,000 after purchasing an additional 1,045,935 shares during the period. Perceptive Advisors LLC lifted its position in shares of Verrica Pharmaceuticals by 40.9% in the 4th quarter. Perceptive Advisors LLC now owns 7,099,182 shares of the company’s stock worth $51,966,000 after purchasing an additional 2,060,199 shares during the period. Vanguard Group Inc. lifted its position in shares of Verrica Pharmaceuticals by 0.6% in the 1st quarter. Vanguard Group Inc. now owns 1,268,710 shares of the company’s stock worth $7,511,000 after purchasing an additional 7,609 shares during the period. Finally, Bank of New York Mellon Corp lifted its position in shares of Verrica Pharmaceuticals by 8.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 58,680 shares of the company’s stock worth $428,000 after purchasing an additional 4,393 shares during the period. Hedge funds and other institutional investors own 42.45% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently commented on VRCA. Needham & Company LLC upped their price target on shares of Verrica Pharmaceuticals from $8.00 to $16.00 and gave the company a “buy” rating in a report on Tuesday, May 14th. HC Wainwright upped their target price on shares of Verrica Pharmaceuticals from $13.00 to $14.00 and gave the stock a “buy” rating in a research note on Tuesday, May 14th.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.